Abbott Laboratories
reported fourth-quarter adjusted earnings that beat Wall Street estimates but sales fell 12% from a year earlier on what the company called an “expected year-over-year decline in Covid-19 testing-related sales.”
Abbott (ticker: ABT) shares were down 1.8% in premarket trading.